TABLE 2.
Clinical characteristics of COVID‐19 non‐ICU and ICU patients
|
COVID‐19 Non‐ICU (N = 20) |
COVID‐19 ICU (N = 15) |
P value | |
|---|---|---|---|
| Age, mean (±SD) | 48.5 (±17.2) | 62.0 (±15.3) | .02 |
| Male, % | 40 | 53 | .51 |
| Hispanic/Latino, % | 30 | 40 | .72 |
| BMI, mean (±SD) | 34.1 (±9.7) | 30.6 (±9.0) | .16 |
| Diabetes, % | 30 | 60 | .10 |
| Hypertension, % | 35 | 53 | .32 |
| Chronic lung disease, % | 15.0 | 26.7 | .67 |
| SOFA score, mean (±SD) | 1.8 (±1.1) | 5.3 (±1.8) | <.001 |
| ARDS, % | 10 | 93.8 | <.001 |
| Mechanical ventilation, % | 0 | 60.0 | <.001 |
| Survival to date, % | 100 | 60 | .003 |
| White blood cell count, mean (±SD) | 6.2 (±2.3) | 8.3 (±2.2) | .009 |
| Platelet count, K/µL, mean (±SD) | 241 (±107) | 244 (±54) | .38 |
| Hydroxychloroquine, % | 20 | 33 | .45 |
| Remdesivir, % | 27 | 25 | >0.99 |
| Anticoagulation, % | 80 | 100 | .12 |
| D‐dimer, median (IQR) | 765 (495‐1382) |
1340 (696‐4297) |
.04 |
| EVTF activity, median (IQR) |
0.24 (0.14‐0.37) |
0.47 (0.30‐0.81) |
<.001 |
| PAI−1, median (IQR) |
66.5 (37.5‐108.6) |
47.7 (38.3‐83.4) |
0.610 |
Study participants were a subset of subjects previously reported. 18 , 23 , 24 Groups were compared using the Mann‐Whitney U test.
Abbreviations: ARDS, acute respiratory distress syndrome; BMI, body mass index; COVID‐19, coronavirus disease 2019; EVTF, extracellular vesicle tissue factor; ICU, intensive care unit; IQR, interquartile range; PAI‐1, plasminogen activator inhibitor‐1; SD, standard deviation; SOFA, sequential organ failure assessment.